Sign up Australia
Proactive Investors - Run By Investors For Investors

Rhythm Biosciences granted European biomarker patent for method of detecting colorectal cancer

Coverage of the company’s ColoSTAT™ antibody-based blood test has been confirmed in 13 countries.
Graphic showing cancer cells
Colorectal cancer is the third largest cause of cancer-related deaths globally

Rhythm Biosciences Ltd (ASX:RHY) has been granted a biomarker patent in Europe for its ColoSTAT™ antibody-based blood test targeting the accurate and early detection of colorectal cancer.

Issuance by the European Patent Office means that coverage of the company’s granted European patent EP 2829881 has been confirmed in 13 countries.

As well as the UK, the countries are Austria, Belgium, Denmark, Finland, France, Germany, Luxembourg, Netherlands, Norway, Sweden, Switzerland and Liechtenstein.

READ: Rhythm Biosciences makes progress in developing colorectal cancer test

Managing director Dr Trevor Lockett said: “In balancing coverage against costs, Rhythm elected to file this pivotal patent family in countries with significant populations and health care systems supportive of cancer preventive strategies.”

The patent claims are geared towards diagnosis or detection of colorectal cancer with a method comprising assessing the presence and/or level of selected combinations of up to 31 biomarkers.

It also relates to diagnostic kits comprising reagents for determining the presence and/or level of selected biomarkers and methods of detecting or diagnosing colorectal cancer.

The European patent’s expiry is July 14, 2031.

Early detection

Colorectal cancer is the second largest cause of cancer death in Australia, Europe and the US, and the third largest cause of cancer-related deaths globally.

ColoSTAT is intended to provide the accurate and early detection of colorectal cancer, acting as either a ‘first-step’ screening test or within the triage of persons with a positive faecal immunochemical test (FIT) or colonoscopy.

As well as being of value to those with colorectal cancer risk factors, ColoSTAT provides an alternative for those who choose not to or are unable to be assessed using standard screening programs.

Commercialisation strategy

Chairman Shane Tanner said: “This is an important milestone for the company.

“With patent rights secured, Rhythm will now begin developing its commercialisation strategy for ColoSTAT in the UK and on the continent.”

Rhythm has previously been granted patents directed towards the diagnosis of colorectal cancer in Australia, China and Japan.

Further patents pending

It has patent applications pending in the US, Brazil and India, and a divisional patent application pending in China.

The culmination of Rhythm’s two-year R&D program, the focus for its first funding round, will be lodgement of applications to the European authorities for a CE mark for ColoSTAT.

Rhythm will also make application to the TGA in Australia for listing of ColoSTAT on the Australian Register of Therapeutic Goods.

Success with these regulatory approvals will allow the company to sell the product in Europe, the UK and Australia via the activation of regionally tailored commercialisation plans.

View full RHY profile View Profile

Rhythm Biosciences Ltd Timeline

Related Articles

surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use